Alzheimer's disease (AD) is an increasingly common disease with massive personal and economic costs. While it has long been known that AD impacts the visual system, there has recently been an increased focus on understanding both pathophysiological mechanisms that may be shared between the eye and brain and how related biomarkers could be useful for AD diagnosis. Here, were review pertinent cellular and molecular mechanisms of AD pathophysiology, the presence of AD pathology in the visual system, associated functional changes, and potential development of diagnostic tools based on the visual system. Additionally, we discuss links between AD and visual disorders, including possible pathophysiological mechanisms and their relevance for improving our understanding of AD.
Introduction
Alzheimer's disease (AD) is a profound public health problem. Alzheimer's disease is the sixth leading cause of death in the United States (US) and results in over $200 billion of annual healthcare spending (Alzheimer's Association 2015). The number of AD cases in the United States is expected to reach over 14 million by 2050 (Hebert et al. 2013) , with similar trends projected globally (Ferri et al. 2005) , primarily due to significant growth of the aged population. While the most prominent deficits that occur in AD are in cognition, a multitude of sensory system dysfunctions (including in the olfactory, auditory, and visual systems) have also been identified (Albers et al. 2015) . Study of the visual system in AD has a rich history: Alois Alzheimer himself identified visual defects in AD's index case, Auguste D, in 1906 (Maurer et al. 1997 . In the modern era, exploring the visual system in AD is especially interesting due to a growing literature exploring pathological changes associated in the retina and brain as biomarkers, in addition to the increasing study of functional alterations. Our goal in this review was to integrate this information in order to improve understanding of how these different lines of evidence fit together to provide insight into how the visual system is altered in AD and may provide insight into mechanisms of AD pathophysiology as well as the development of powerful diagnostic tools.
Clinical Background
Alzheimer's disease (AD) is the most common form of dementia and has a strong association with age-about 15% of the population over the age of 65 has AD (Alzheimer's Association 2010). Over 5 million people in the United States (US) have AD, with >95% having the sporadic, late-onset (after age 65) variant and far fewer than 5% having the autosomal dominant, early-onset variant (Alzheimer's Association 2010). The clinical course of AD is currently best understood as consisting of an extended prodromal stage during which pathology may accumulate without symptoms, an early clinical manifestation of memory and cognitive defects once pathology and associated neural injuries reach a threshold, and later severe cognitive and functional declines (Sperling et al. 2011; Galvin & Sadowsky 2012) . On average, death occurs approximately 8 years after diagnosis (Alzheimer's Association 2015).
While probable AD can be diagnosed based on clinical criteria, AD is only definitively diagnosed at autopsy with the detection of two hallmark neuropathology findings: extraneuronal plaques consisting primarily of aggregated Ab protein and intraneuronal neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein (Serrano-Pozo et al. 2011; Beach et al. 2012) . Cerebrospinal fluid (CSF) levels of Ab42 and tau protein are established biomarkers for AD (Scheltens et al. 2016) and may now aid in diagnosis. Brain imaging with MRI and FDG PET are also established options to aid diagnosis, with more specialized techniques used to visualize Ab and tau in vivo (e.g. RGC PET) emerging as diagnostic potentialities (Scheltens et al. 2016) . Additional biomarkers may provide improved diagnosis of AD while increasing cost efficiency if less invasive methods can be developed that do not require expensive brain imaging. In particular, diagnostics based on visual system pathology and functional alterations are promising in this regard (see section below on AD pathology in the visual system).
At present, there are two types of pharmaceuticals approved to treat AD symptoms: cholinesterase inhibitors (e.g. donepezil) and NMDA receptor antagonists (memantine) (Mufson et al. 2009; Kumar et al. 2015) . However, there are no diseases modifying therapies currently available (Cummings et al. 2014 ). Alzheimer's disease (AD) pathophysiology is thought to involve effects of the Ab and tau proteins leading to synapse loss and, ultimately, to neurodegeneration (Selkoe 2002) . Indeed, the majority of AD therapeutics in development focuses on either limiting the production of Ab or accelerating its removal from the brain (Mangialasche et al. 2010) . Notably, it is now thought that AD treatment should begin as early as the prodromal phase in order to optimize therapeutic efficacy, increasing interest in identifying biomarkers useful for initiating and evaluating treatment.
Molecular Pathophysiology
The pathophysiology of AD is complex and multifactorial. Numerous processes including neuroinflammation, metabolism, oxidative stress, vascular dysfunction, and genetic factors are also thought to be important (Johnson et al. 2010; Swerdlow et al. 2010; Mayeux & Stern 2012; Sagare et al. 2012; Tanzi 2012; Iadecola 2013; Heneka et al. 2015) . Considerable research has focused on the roles of the Ab and tau proteins in the disease. While the relationship between these two proteins is not clear, both are known to cause pathophysiological effects in experimental models (Selkoe 2002; Karran et al. 2011; Spires-Jones & Hyman 2014) . Ab is thought to be the central driver of the disease, in part due to the existence of early-onset forms of AD that occur in patients harbouring mutations of proteins involved in the generation of Ab from precursor proteins (Hardy & Higgins 1992) . Ab is produced through the processing of the amyloid precursor protein (APP), an integral membrane protein, via sequential cleavage by b-secretase and c-secretase (to release a 40-or 42-amino acid peptide) . The 42-amino acid form of Ab (Ab42) is more prone to form aggregates and is thought to be the primary toxic form of Ab (Nelson et al. 2009 ). Notably, mutations in APP itself, or more commonly, in the presenilin 1 (PS1) or presenilin 2 (PS2) components of csecretase are associated with earlyonset AD (Holtzman et al. 2011) .
The central role of Ab as a driver of AD pathophysiology is often referred to as the amyloid cascade hypothesis, in which the accumulation and aggregation of Ab into plaques and soluble oligomers leads to a multitude of downstream effects harming synaptic function and ultimately resulting in cell death (Hardy & Higgins 1992; Selkoe 2002) , although this hypothesized model of AD pathophysiology has been hotly debated within the field, and remains unproven by clinical interventions (Herrup 2015) . Ab is prone to aggregate in large extracellular plaques and also soluble oligomers, the latter of which is thought to be the primary toxic species (Shankar et al. 2008; Koffie et al. 2011) . There is considerable evidence that Ab (particularly oligomers) impairs synaptic plasticity, with effects on long-term potentiation (a measure of synaptic efficacy), and ultimately leads to synapse loss (Shankar et al. 2007 (Shankar et al. , 2008 Li et al. 2009 Li et al. , 2011 . Notably, tau also has deleterious effects on synaptic function (Hoover et al. 2010; Pooler et al. 2014 ). Due to these effects, Ab and tau deposition in different brain regions is important to mediating potential functional effects of AD pathology. This holds true for the effects of AD in the visual system.
Neuropathology
As noted above, AD is definitively diagnosed at autopsy with the detection of two hallmark neuropathology findings: Ab plaques and tau NFTs (Serrano-Pozo et al. 2011; Beach et al. 2012) . Multiple studies have evaluated the regional distribution of Ab and tau pathology in clinically diagnosed AD patients and aged controls (Braak & Braak 1991 Braak et al. 2011; Serrano-Pozo et al. 2011) . Both Ab pathology and tau pathology have been found at different levels of the visual system. Detectable AD pathology appears to originate at different times in different parts of the brain (Fig. 1) . The classic view is that AD pathology first appears in the medial temporal lobe and that brain regions directly associated with the visual system are only involved relatively late in the disease. Interestingly, the mechanism of how AD pathology appears in different brain regions is unknown. It is possible that alterations in brain network activity (due to neuronal injury or other factors) and/or cumulative dysfunction in amyloid clearance allow for pathology to accumulate in connected brain regions. However, an intriguing possibility is the misfolded protein seeds allow for pathology to be directly propagated throughout brain networks, although this has not been proven (Walker et al. 2012; Walsh & Selkoe 2016) .
Specifically, AD pathology has been found in both cortical and subcortical regions associated with visual function (Albers et al. 2015) , in addition to in the eye itself. Ocular motor function is known to be disturbed in AD (Molitor et al. 2015) . Notably, both Ab plaques (Leuba & Saini 1995) and NFTs (Iseki et al. 1989; Parvizi et al. 2001 ) have been found in AD patients in the superior colliculus, a midbrain region that plays an important role in selecting and initiating eye movements, as well as in mediating visuospatial attention and a variety of other related sensorimotor tasks (King 2004; Krauzlis et al. 2004; Wolf et al. 2015) . Additionally, Ab plaques have been found in AD patients in the pulvinar nucleus of the thalamus (Kuljis 1994) , which has proven important in mediating eye movements, including saccades (Berman & Wurtz 2010) . Another subcortical region that has been demonstrated to have Ab plaques in AD patients is the lateral geniculate nucleus, a fundamental relay centre for projections from retinal ganglion cells (RGCs) to higher-order cortical areas (e.g. primary visual cortex). Pathology in the lateral geniculate region may play an important role in the visual processing defects demonstrated in AD patients (Chang et al. 2014 ). An additional subcortical area in which NFTs accumulate in AD patients is in the suprachiasmatic nucleus (Stopa et al. 1999) . The suprachiasmatic nucleus plays a key role in generating circadian rhythms and receives projections from RGCs. Interestingly, the interplay between sleep, circadian biology, and Ab metabolism and clearance from the brain has emerged as an important topic in understanding AD pathophysiology (Musiek et al. 2015) .
The visual cortex has been comparatively well studied in relation to AD. While the primary and associative visual cortices are often considered to be relatively spared in AD (i.e. impacted later), pathological findings consistent with AD are found in these areas later in disease progression (Leuba & Saini 1995) . The pathology that occurs in the visual cortex consists of both Ab plaques and NFTs. However, it is important to note there is evidence that NFTs and Ab plaques appear in the visual association cortex in many aged cognitively normal individuals, in addition to mild cognitive impairment (MCI) and AD patients, occasionally without corresponding pathology in the medial temporal lobe (McKee et al. 2006) . Posterior cortical atrophy (PCA) has been described a visuospatial variant of AD in which patients present with visual agnosia and neglect, in addition to defects in eye fixation and saccadic and pursuit movements (Shakespeare et al. 2015) . Posterior cortical atrophy patients have occipital and parietal atrophy and AD pathology (particularly NFTs) early in the disease course in the primary and secondary visual cortex (Leuba & Saini 1995; Tang-Wai et al. 2004; McKee et al. 2006; Su arezGonz alez et al. 2015) . Notably, pathology in visual regions may appear earlier and cause functional deficits in other neurodegenerative syndromes that overlap with AD and PCA, including Balint's syndrome (Beh et al. 2015) and corticobasal syndrome variants, such as Gerstmann syndrome (Di Stefano et al. 2016).
Retina
The retina is considered a window to the brain as it is composed of RGCs which combine their axons to form the optic nerve and travel to the occipital lobe. Therefore, there is potential to utilize data from the retina in developing biomarkers for AD, as the retina may undergo similar pathological changes. Despite the strong association of AD with Ab plaques and NFTs, reports disagree as to their presence in P T Fig. 1 . Visual system manifestations of Alzheimer's disease (AD): In this schematic of the visual system, the alterations found in AD patients are demonstrated in the right hemisphere. The hallmark pathological findings of AD, amyloid plaques, and tangles composed of tau, are found in multiple brain regions associated with visual function, including the visual cortex, and subcortical areas such as the pulvinar nucleus, lateral geniculate nucleus, suprachiasmatic nucleus, and superior colliculus; pathology in these regions is tied to alterations in associated functions. In the eye, the optic nerve degenerates in AD patients, with loss of axonal projections. Additionally, there is reduced retinal thickness and diminished retinal vasculature in AD patients.
the retina (and optic nerves) of AD patients. Earlier studies found a lack of evidence for Ab plaques or NFTs in these areas (Hinton et al. 1986; Blanks et al. 1989; Ho et al. 2014) . While additional studies have described the presence of Ab plaques and NFTs in the retinas of AD patients (Koronyo et al. 2012a,b; Frost et al. 2014 (Paquet et al. 2007; Kesler et al. 2011; Coppola et al. 2015) . The changes to the retinal nerve fibre layer (RNFL) have been documented in early AD patients who lack visual impairment, suggesting that this change occurs early in the AD course and indicating potential diagnostic relevance (Lu et al. 2010; Kirbas et al. 2013; Bambo et al. 2014; Garcia-Martin et al. 2014 ). In addition, these changes may be indicative of disease severity, as it has been shown that RNFL thickness is inversely correlated with duration of AD as well as AD severity (Iseri et al. 2006; Bambo et al. 2015a; Garcia-Martin et al. 2016 ) and therefore may be a potential biomarker (Tas et al. 2015) . Interestingly, while a smaller study failed to find a correlation between RNFL and AD specific data, the investigators did find a correlation between fluorescence lifetime imaging ophthalmoscopy (FLIO) parameters and AD severity, indicating disease-specific substances within the retina (Jentsch et al. 2015) . Specifically, this study described a significant correlation between minimental status examination (MMSE) and phosphorylated tau protein obtained from CSF with fluorescent imaging changes in the AD retina (Jentsch et al. 2015) . It is therefore tempting to speculate that retinal imaging, via OCT or via FLIO, may be a useful AD diagnostic tool related to disease course.
While the mechanism of RNFL reduction has yet to be elucidated, proposed hypotheses include Ab plaques and NFTs disrupting normal retinal cell function, reduced vascularization, retrograde degeneration from loss of cortical neurons or inflammation. Interestingly, this reduction in RNFL has also been found with other neurodegenerative disorders, notably Parkinson's disease and dementia with Lewy bodies (Moreno-Ramos et al. 2013 ). Specific to the macula, studies have demonstrated reduced macular thickness, decreased electrical activity of the macula, decreased macular pigment concentration and increased occurrence of age related macular degeneration (AMD) (Moschos et al. 2012) . It is informative to discuss the relationship of AD to AMD, in which retinal drusen is known to contain Ab. Interestingly, the APOE gene, which encodes a protein, apolipoprotein E, with a broad array of functions, including lipid transport and impacts on Ab metabolism, is the primary known genetic risk factor for late-onset AD and also is implicated in AMD pathophysiology (Mahley & Rall 2000; Wolf et al. 2013) . Recently, Ab has been proposed as a driving factor in the degeneration that occurs in AMD (Ratnayaka et al. 2015) . While more evidence is needed to elucidate this relationship, the mechanics of how Ab damages the retina in AMD may have implications for understanding the possibly similar process that occurs in AD.
In addition to AMD, an association of glaucoma with AD has been proposed and is under investigation. Glaucoma is associated with a loss of RGCs and optic nerve degeneration, which can lead to blindness. These changes are functionally similar to those that occur in AD patients. Multiple studies have found an increased occurrence rate of glaucoma in patients who have AD (Bayer et al. 2002a,b; Tamura et al. 2006; Lin et al. 2016) , while others have not (Kessing et al. 2007; Bach-Holm et al. 2012; Ou et al. 2012; Keenan et al. 2015) . Several hypotheses have been proposed as to the association of glaucoma and AD. One such hypothesis is that the association is due to changes in CSF (Wostyn et al. 2009 ). Specifically, reduced CSF pressure in AD patients may lead to functional alterations of the lamina cribrosa, a structure located in the posterior sclera which functions to stabilize the intraocular and extraocular pressure gradient (Jonas et al. 2003) . Therefore, reduced CSF in AD patients may affect the pressure gradient and may lead to glaucomatous-like changes. Another hypothesis involves defective Ab clearance due to disruptive CSF circulation, which has also recently been coined dysfunctional glymphatics (Iliff et al. 2012; Wostyn et al. 2014 Wostyn et al. , 2015 Wostyn et al. , 2016 . Despite these proposed hypotheses, however, the data are still unclear as to whether a true association exists between AD and glaucoma. A systematic review of these association studies concluded that due to a lack of consensus in published data, further longitudinal studies are required (Tsilis et al. 2014) . Additionally, two published record linkage studies failed to find increased risk of AD in patients with primary open angle glaucoma (Kessing et al. 2007; Keenan et al. 2015) . Therefore, further studies are warranted to elucidate these associations and mechanisms.
Vascular abnormalities have also been associated with AD, and in fact, a vascular hypothesis of AD postulates that reductions in cerebral blood flow may serve as a useful biomarker (Wierenga et al. 2014; Hays et al. 2016) . Given the ability to visualize vasculature of the retina in a noninvasive manner, the retina has been used to assess microvascular changes in AD patients. Not surprisingly, studies in AD patients have shown a reduction in retinal microvasculature (Cheung et al. 2014; Williams et al. 2015) which has been correlated with optic nerve head paleness in early AD (Berisha et al. 2007 ). Other vasculature findings in AD include narrowing of a retinal veins (Bambo et al. 2015b) , reduced blood flow (Feke et al. 2015) and reduced choroidal thickness (Bayhan et al. 2015) . Consistent with these findings, significantly increased retinal oxygen saturation in both arterioles and venules of AD patients has been shown (Einarsdottir et al. 2015) . The timeline of these retinal changes is interesting and in debate, as reductions in cerebral blood flow have been shown to occur prior to the onset of symptoms (Berisha et al. 2007; Wierenga et al. 2014; Hays et al. 2016) . Whether these retinal vasculature changes can be visualized prior to any cognitive symptoms, and thus used as a potential biomarker, has yet to be established.
An emerging area of study is how eye injuries are associated with AD pathology. Axonal injury associated with traumatic brain injuries (TBIs) has increasingly been linked to increases in AD-associated pathological markers (e.g. Ab) in cortical and subcortical regions (Johnson et al. 2010) . Although not definitive, multiple epidemiological studies have linked TBI with increased risk of developing AD (Sivanandam & Thakur 2012; Barnes et al. 2014) . Interestingly, data from animal models and human studies suggest that TBI without frank eye trauma can result in increases in ADassociated proteins in the retina, as well as the optic nerve. In rodent models of TBI, tau and APP reactivity are increased in injured axons and there is associated RGC loss as measured by histology and OCT (Mohan et al. 2013; Xu et al. 2015 Xu et al. , 2016 . In humans, histological studies show that APP reactivity is similarly increased in the retina following paediatric head trauma (Gleckman et al. 2000; Reichard et al. 2004; Bais et al. 2015) . Given that APP metabolism is closely linked to Ab production, any increases in APP expression or processing induced by injury may increase the formation of toxic Ab aggregates. In fact, Ab plaques are often present following TBI in humans, but studies in animal models have failed to reach consensus on how any such plaques are formed (Johnson et al. 2010) . Therefore, with further exploration of this phenomenon, it may be possible via retinal imaging both to improve the diagnosis of TBI and to better understand the dynamics of AD pathology in the nervous system, which has important implications for AD risk.
Optic Nerve
The optic nerve is comprised of retinal nerve cell axons which combine and travel to the occipital lobe for visual information processing. Seminal work by Hinton et al. (1986) demonstrated widespread axonal degeneration in the axonal segments of the optic nerve in autopsy samples from AD patients. Follow-up studies have not come to agreement about which specific contributory fibres are most affected by the disease process, variably reporting reductions in optic nerve volume via both loss of large calibre axons and small calibre axons (Blanks et al. 1989; Sadun & Bassi 1990; Tsai et al. 1991; Danesh-Meyer et al. 2006 ). However, recent work using diffusion tensor imaging (DTI) demonstrated significant changes in the optic nerves of AD patients compared to age-matched controls and these findings were noted to be less severe in patients with MCI, a precursor state to AD (Nishioka et al. 2014) , suggesting a progressive deterioration. Specifically, DTI showed increases in the total diffusivity, radial diffusivity and fractional anisotropy in the optic nerves of AD patients, correlating with reduced function and suspected axonal degeneration (Nishioka et al. 2014) . In vivo monitoring of the optic nerve volume can be ascertained by measurement of the cup-to-disc ratio. Indeed, patients with AD have been shown to have a higher cup-todisc ratio compared to age-matched controls, which correlates with a loss of optic nerve thickness (Tsai et al. 1991; Danesh-Meyer et al. 2006) . The question remains regarding the specificity of this measurement, however, as an increased cup-to-disc ratio has been documented among many other pathological conditions.
Lens
Outside of the retina, cytosolic Ab proteins have been found in the lens, aqueous humour and vitreous humour of AD patients (Goldstein et al. 2003; Yoneda et al. 2005) . Although the clinical significance of these limited findings is not clear, there may be an association between AD and cataracts, specifically in the supranuclear region (Goldstein et al. 2003) , although studies have been inconsistent (Michael et al. 2013 (Michael et al. , 2014 Ho et al. 2014) . Interestingly, Down's syndrome patients, who have an extra copy of chromosome 21 (which contains the gene for APP), are thought to have comparable cataracts (Moncaster et al. 2010 ). However, a clinical study demonstrated that lens opacity was not a valuable indicator of preclinical AD (Bei et al. 2015) . Of note, there is a more significant literature exploring lens pathology in AD animal models (Parnell et al. 2012; Javaid et al. 2016) .
Functional Alterations
Given the significant visual system manifestations of AD, there is increased interest in examining potential to use the functional changes present in the visual system to aid in the diagnosis of the disease. As mentioned, AD diagnosis currently requires post-mortem analyses of brain tissue to identify Ab plaques and NFTs. Additionally, while biomarkers and brain imaging can now aid in diagnosis, discovery of additional reliable and inexpensive methods to diagnose AD could significantly alter the ability to initiate and guide prospective treatments. As such, analysis of various ocular functions has been proposed as potential diagnostic tools including mydriatic and miotic response, pupillary light reflex, ocular motor function, visual fields and acuity, contrast sensitivity, colour vision, depth perception, motion perception and electrophysiological response (Rizzo et al. 2000; Chang et al. 2014; Tzekov & Mullan 2014; Javaid et al. 2016) . Importantly, many of these functional changes can be related to the loss of acetylcholine neurons in AD patients and their use as early biomarkers has been explored. However, it is important to consider that many of these changes can also be seen in other forms of dementia, including Parkinson's disease, and thus may not be specific to AD (Weil et al. 2016) . While conclusive data are limited on the usefulness of any one of these techniques, collectively, they represent an important area of study.
For instance, while pupil reaction changes have been proposed as a diagnostic, the literature is divided on its efficacy. Tropicamide (0.01%) is an anticholinergic drug used for pupil dilation and an early studies reported a greater pupil dilation with its use in AD patients when compared to controls (Scinto et al. 1994a,b) . However, since then, subsequent studies have failed to reproduce this result and the response was shown to be non-specific (Fitzsimon et al. 1997; Growdon et al. 1997; Iijima et al. 2003) . Two further studies reported the difference between AD and control pupil dilation is obtained with a diluted dosage of tropicamide (0.005%) and thus proposed using this as a diagnostic technique (Iijima et al. 2003; Mahmoudian et al. 2009 ). Pilocarpine, a cholinergic agent, has also been proposed as an AD diagnostic with evidence of increased miotic response in AD patients compared to controls (Kaneyuki et al. 1998; Hanyu et al. 2007 ). However, these findings have additionally been reported in depression (Sokolski & Demet 1996) and Lewy body dementia (Hanyu et al. 2007 ) and therefore are of questionable specificity. Without the use of cholinergic or anticholinergic agents, AD patients have a shorter latency and lower amplitude response of pupillary light reaction when compared to controls (Fotiou et al. 2000 (Fotiou et al. , 2007 , which is consistent with reports of decreased sympathetic activity. This has been proposed as a non-invasive diagnostic tool for AD (Fotiou et al. 2007) . However, as with many other pupil response tests, the specificity of such a test must be considered, as studies have found similar results in Down's syndrome and Parkinson's disease. Therefore, further controlled studies are required to elucidate its utility. Despite this lack of specificity, it is nevertheless tempting to consider these changes in cholinergic responses an indicator of the widespread loss of cholinergic activity occurring in AD brains.
Contrast sensitivity, the ability to detect visual stimuli among varying background noise, has been found to be impaired in AD patients and the use of the cholinergic agent, donepezil, leads to increased sensitivity and accuracy in control non-AD patients (Boucart et al. 2015) . Various animal and human studies have shown contrast sensitivity is largely modulated via acetylcholine signalling (Gilmore & Whitehouse 1995; Risacher et al. 2013; Soma et al. 2013a,b) ; thus, it is not surprising to see such changes in AD patients. Furthermore, AD patients treated with donepezil have improved measures of visual selective attention (Foldi et al. 2005) , which has been shown to be impaired in AD patients (Chau et al. 2015) . Given the loss of acetylcholine neurons in AD patients and the effects of donepezil on these visual functions, the implication for its use as a biomarker has been raised (Foldi et al. 2005; Boucart et al. 2015) . However, it is again important to consider the specificity of these biomarkers as contrast sensitivity and colour vision, among other functional deficits, have been shown to be reduced in Parkinson's disease patients as well (Weil et al. 2016) . Ocular motor function changes, such as impaired saccades, fixation and vergence, have been documented in AD patients (Chang et al. 2014) . Ocular motor impairment may be considered an early feature of AD prior to the onset of other symptoms (Scinto et al. 1994a,b) . In addition, patients at high risk for AD can be identified from patients at low risk for AD using ocular motor testing with a sensitivity of 82% and a specificity of 91% (Hawkins & Sergio 2014) . Therefore, the evaluation of probable AD patients using ocular motor function tasks has been proposed as diagnostic (Scinto et al. 1994a,b) .
Visuospatial processing and perception (VSP) is also dysfunctional in AD patients (Mandal et al. 2012) . Visuospatial processing and perception is considered an integrated visual function due to requirement of associative and visual cortices, as well as higher cortical function for processing. One earlier study using fMRI to monitor VSP found that functional ability was highly correlated with VSP performance and concluded that VSP should be considered a cognitive predictor of such functional abilities (Perry & Hodges 2000; Mandal et al. 2012) . This reduced VSP function is exemplified in the classic clock drawing test (CDT), in which patients are verbally instructed to draw a clock set to a specified time (Mandal et al. 2012) . Patients with probable AD perform poorly in this task. fMRI studies have shown various regions of brain function to be utilized during CDT and because of this, CDT score may reflect AD severity and course (Cahn-Weiner et al. 1999; Ueda et al. 2002; Thomann et al. 2008; Mandal et al. 2012) . Clock drawing test is an important component of our current evaluation of dementia and is widely used globally today. However, as with many of these functional deficits seen in AD patients, similar deficits can be seen in patients with other forms of dementia, including Parkinson's disease (Tan et al. 2015) . Although these tests may show potential and their general ease of in-officeprovider-use leads to their hopeful consideration, future studies are warranted to determine their utility.
Conclusions
Alzheimer's disease (AD) is a major threat to public health. That AD impacts the visual system is increasingly recognized, with pathology studies demonstrating presence of AD markers in multiple visually associated brain areas, as well as certain components of the eye. Evidence from the visual system may provide increasing evidence in attempts to understand the pathophysiology of AD, notably by looking at how the retina is impacted by ADassociated pathology. As tools improve, we expect that the preliminary findings attempting to detect these pathological changes in AD patients will become more robust, and may lead to the development of new non-invasive tests to aid in the diagnosis of AD, utilizing the eye as a brain window. While the data supporting clinical tests relying on visual functional changes in AD remain rudimentary, these tests represent an additional opportunity to aid in the detection of AD, and the ability to help effectively screen patients and subsequently guide treatment.
